ClinicalTrials.gg

Program

RC1416

A development code. Also written as “RC1416(SAD)”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by Nanjing RegeneCore Biotech.

Furthest: phase 2, since Jan 27, 20264 company-led studies, 2 open or runningNext primary completion: Oct 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing RegeneCore Biotech42 open or runningphase 2since Jan 27, 2026Sep 12, 2023Oct 25, 2027phase 2 · NCT07403487

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2023First study: phase 1 study in Healthy VolunteersFirst studyNCT06067490 · 48 enrolled · China
  2. Mar 28, 2025Phase 1 study in Moderate to Severe AsthmaNCT06911866 · 40 enrolled · China
  3. Jan 27, 20262 phase 2 studiesPhase 2 reachedNCT07403487, NCT07402551

Ahead

  1. Oct 25, 2027Primary completion: phase 2 study in Moderate to Severe AsthmaNCT07403487
  2. May 31, 2028Primary completion: phase 2 study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT07402551

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) · China2RecruitingMay 31, 2028180
NCT07403487Moderate to Severe Asthma · China2RecruitingOct 25, 2027195
NCT06911866Moderate to Severe Asthma · China1CompletedSep 25, 202540
NCT06067490Healthy Volunteers · China1CompletedMay 14, 202448

How it is read

Names in the registry

  • “RC1416”, 3 entries
  • “RC1416(SAD)”, 1 entry

Codes read as this program: RC1416.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.